Essential hypertension is a disease multifactorially triggered by genetic and environmental factors. The contribution of genetic polymorphisms of the renin-angiotensin-aldosterone system and clinical risk factors to the development of resistant hypertension was evaluated in 90 hypertensive patients and in 115 normotensive controls living in Southwestern Brazil. Genotyping for insertion/deletion of angiotensin-converting enzyme, angiotensinogen M235T, angiotensin II type 1 receptor A1166C, aldosterone synthase C344T, and mineralocorticoid receptor A4582C polymorphisms was performed by PCR, with further restriction analysis when required. The influence of genetic polymorphisms on blood pressure variation was assessed by analysis of the odds ratio, while clinical risk factors were evaluated by logistic regression. Our analysis indicated that individuals who carry alleles 235-T, 1166-A, 344-T, or 4582-C had a significant risk of developing resistant hypertension (P < 0.05). Surprisingly, when we tested individuals who carried the presumed risk genotypes A1166C, C344T, and A4582C we found that these genotypes were not associated with resistant hypertension. However, a gradual increase in the risk to develop resistant hypertension was detected when the 235-MT and TT genotypes were combined with one, two or three of the supposedly more vulnerable genotypes -A1166C (AC/AA), C344T (TC/TT) and A4582C (AC/CC). Analysis of clinical parameters indicated that age, body mass index and gender contribute to blood pressure increase (P < 0.05). These results suggest that unfavorable genetic renin-angiotensin-aldosterone system patterns and clinical risk variables may contribute to increasing the risk for the development of resistant hypertension in a sample of the Brazilian population.
Introduction
Essential hypertension, a complex syndrome determined by both genetic and environmental factors, affects approximately 25% of the world's population and consequently is considered to be one of the most common conditions for which individuals seek health care. According to the National Health and Nutrition Education Survey (1), most hypertensive patients are considered to be resistant because their blood pressure (BP) cannot be reduced to <140/90 mmHg with an appropriate triple-drug regimen, including an oral diuretic, with all agents administered at or near maximal dosages. Moreover, careful elimination of patient-and physicianrelated reasons of inadequate blood pressure control should lead to the diagnosis of truly resistant hypertension. The causes of refractory hypertension are multifactorial and therefore a better understanding of the physiological systems that contribute to this uncontrolled BP and of drug metabolism may help identify the causative factors.
In the past, genetic polymorphisms of candidate genes from physiological systems involved in BP control have been extensively tested. The renin-angiotensin-aldosterone system (RAAS) is one of the mechanisms that play key roles in the regulation of BP. Consequently, genes that encode components of the RAAS are thought to play a role in determining genetic susceptibility to essential hypertension and have been intensively scrutinized. Some of the polymorphisms associated with the various forms of hypertension are: the methionine (M) → threonine (T) variation at the amino acid position 235 of the angiotensinogen (AGT) gene (2) , an insertion/deletion of the Alu fragment in the 16th intron of angiotensinconverting enzyme (ACE) (3), an A to C transversion at the nucleotide position 1166 of the AGT II receptor type 1 (AGTR1) (4) and the T → C substitution at the -344 locus in the promoter region of aldosterone synthase (CYP11B2) (5) . Most of these polymorphisms are involved in specific physiological imbalance (6) (7) (8) . However, contradictory findings have been obtained for different populations (9) (10) (11) (12) (13) (14) . The inconsistencies presented in RAAS gene-association studies exemplify the challenges of distinguishing among complex multifactorial traits, such as hypertension, by single-locus analysis. These inconsistencies might arise from population structure, varying effects of several disease-predisposition variants or geneenvironment interactions. Each of these factors can hinder the detection of a modest contribution by an individual locus to a trait such as hypertension. Subsequently, the screening of numerous molecular variations combined with environmental-clinical factors may help to elucidate the most important parameters that contribute to disease development in a particular population.
Assuming that hypertension is a result of a complex sum of external and clinical factors combined with genetic predisposition, we determined whether or not multiple polymorphisms in the RAAS pathway genes, as well as environmental-clinical risk factors, contributed to the development of resistant hypertension in a sample of Brazilian patients.
Subjects and Methods

Study subjects
A total of 205 Brazilian individuals (90 hypertensive and 115 normotensive subjects) from the city of Rio de Janeiro with similar anthropometric backgrounds were selected at the Hypertension Division of the Laranjeiras National Institute of Cardiology, Rio de Janeiro, RJ, Brazil. The hypertensive patients recruited had a diagnosis of uncontrolled hypertension based on conventional BP measurements (systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg) (15) (16) (17) and had been under treatment for ≥3 Polymorphism in hypertensive patients www.bjournal.com.br months with a stable scheme consisting of ≥3 antihypertensive drugs (including a diuretic), of adequate combination and dose (15) . In patients with type 2 diabetes (15 individuals) the definition of hypertension was BP ≥130/80 mmHg. Cases with secondary form hypertension were excluded. Normotensive controls were defined as those without a family history of hypertension or other cardiovascular disorders and BP <140/ 90 mmHg. BP was measured on the left arm of the subject in the sitting position with a conventional mercury sphygmomanometer on three different occasions by the same observer (15) .
The study was approved by the Committee for Research on Human Subjects of the Laranjeiras National Institute of Cardiology, and all subjects gave written informed consent to participate.
Genotyping protocols
Genomic DNA was extracted by a standard salting out method (18) . Genotyping was performed by the PCR technique complemented with further restriction enzyme analysis when required. PCR was performed with a Perkin-Elmer 9600 apparatus. For all polymorphisms, 100 ng genomic DNA was amplified. PCR for all the markers was performed using 200 µm of each deoxynucleotide triphosphate, 300 µm of each primer and 0.5 U of Taq polymerase in its specific buffer (Biotools, Mountain View, CA, USA) in a final volume of 10 µL. ACE gene I/D (19) , AGT M235T (20) , AGTR1 A1166C (21), CYP11B2 C344T (22), and mineralocorticoid receptor A4582C (23) were detected by PCR as described elsewhere. ACE PCR fragments were separated on 2.5% agarose gel and visualized by ethidium bromide staining. PCR products were digested with 5 U Tth111I (AGT M235T), DdeI (AGTR1 A1166C), HaeIII (CYP11B2 C344T), and MspA1I (MR A4582C) restriction enzymes (New England Biolabs, Beverly, MA, USA) at 37ºC overnight. The fragments were separated on 3% agarose gels and stained with ethidium bromide and a Polaroid photo was taken for genotyping.
For quality control of these assays, samples from the hypertensive and normotensive groups were selected for regenotyping.
Statistical analysis
Clinical data were compared by the Student unpaired t-test for quantitative data and by the χ 2 test for qualitative data. The genotype frequencies among the study participants were calculated using the SPSS statistical program, version 10.0 (Chicago, IL, USA), and allele frequencies were calculated based on the observed genotypes. The estimation of acceptable minor allelic frequency for RAAS polymorphisms was calculated by the following function:
where α = 5% confidence interval; C = numbers of alleles; n = number of individuals (24) . Hardy-Weinberg equilibrium (HWE) for the distribution of the genotypes was estimated by the χ 2 test using the GENIOC program (25) . Allele and genotype frequencies were compared using χ 2 test, by GENIOC. The influence of each RAAS polymorphism on blood pressure variation was assessed by analysis of odds ratio (OR) (Epi-Info statistical program, version 3.2.2, Atlanta, GA, USA). Next, we selected the genotypes whose association with arterial hypertension had already been established in previous studies, searching for the presence of additive effects of different RAAS polymorphisms by OR analysis. Logistic regression analysis of gender, age, glucose, body mass index (BMI), triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol was used to investigate the association between the anthropometric profile and the risk for hyper-S.R.S. Freitas et al.
www.bjournal.com.br an increased risk for hypertension in this population) were expressively higher in hypertensive patients (235-T allele = 51.6%; 344-T allele = 61.5%) than in controls (235-T allele = 25.2%; 344-T allele = 38%). Comparative analyses of the allelic frequencies of I/D, A1166C, and A4582C did not show differences between groups.
The genotypic frequencies of M235T (P = 0.000), A1166C (P = 0.007), C344T (P = 0.003), and A4582C (P = 0.0492) differed significantly between groups due to the low frequency of at-risk alleles from the M235T (235-MM genotype), A1166C (1166-CC genotype), C344T (344-CC genotype), and A4582C (4582-AA genotype polymorphisms) in the normotensive subjects. The frequency of I/D polymorphisms did not differ between groups (P > 0.05).
To investigate the genetic susceptibility to the development of resistant hypertension we performed OR analysis of the RAAS loci ( Table 3 
Results
The data concerning the clinical parameters of the normotensive and hypertensive groups reported as means ± SD are summarized in Table 1 . A statistically significant difference was observed between the two groups with respect to age, blood pressure level, and lipid profile (P < 0.05).
The minimal allelic frequencies calculated for the hypertensive and normotensive groups were 0.020 and 0.042, respectively. All allelic frequencies in both samples were higher than the predetermined minimum.
The genotypic and allelic frequency data for the hypertensive and normotensive groups are summarized in Table 2 . Tests for HWE were carried out for all loci among the hypertensive and normotensive subjects separately. All polymorphisms analyzed were in HWE not only in patients (P > 0.05) but also in normotensive subjects (P > 0.05).
The allelic frequencies of M235T (P = 0.000) and C344T (P = 0.003) differed significantly between the normotensive and hypertensive groups. In both cases, the 235-T and 344-T alleles (considered to represent (26, 27) .
Discussion
Arterial hypertension involves interactions among genetic, environmental, demographic, vascular, and neuroendocrine factors. Essential hypertension is the most frequent diagnosis in this syndrome, indicating that the etiology has not been identified. However, a number of risk factors underlying essential hypertension have also been identified, including age, sex, and genetics. In some cases, the control of environmental risk factors associated with an appropriate drug/dose can normalize BP. However, patients with resistant hypertension probably have a genetic background that interferes Data are reported as number of subjects or patients with percent in parentheses. ACE = angiotensin-converting enzyme; MR = mineralocorticoid receptor; A4582C = an A to C transversion at the nucleotide position 4582. *P < 0.05 compared to normotensive subjects (χ 2 test).
with BP maintenance or with the pharmacokinetic/pharmacodynamic drug response. Previous studies have demonstrated that polymorphisms of the RAAS genes are related to several physiological changes (21) (22) (23) 28, 29 OR analysis suggested that M235T, A1166C, C344T, and A4582C, tested individually, increased the risk for resistant hypertension. Intriguingly, combinations between A1166C, C344T, and A4582C were not associated with high-blood pressure phenotypes. However, it is very interesting to point out that a gradual risk increase towards resistant hypertension occurs when AGT-MT and TT genotypes are combined with A1166C, C344T, and A4582C genotypes in profile of resistant hypertensive patients and normotensive individuals. The comparative analysis of allelic and genotypic frequencies established that A1166C polymorphism was expressed differently in the normotensive and hypertensive groups. The 1166-A allele, considered to be protective against hypertension according to Benetos et al. (30) and Nalogowska-Glosnicka et al. (21) , was associated with resistant hypertension in our population sample. Almost 85% of patients had the 1166-A allele. These controversial results may be a sign of the relationship between 1166-A and C alleles indicating a different origin of hypertension. For this correlation to be confirmed, the physiological damage caused by this nucleotide alteration must be elucidated.
Comparative analysis also showed an increased frequency of 235-T and 344-T alleles as well as 235-TT and 344-TT genotypes in hypertensive individuals, as encountered in comparative gene-disease analysis (2, 8) or in population studies (11) (12) (13) (14) . The A4582C polymorphism has failed to reveal any correlation with hypertension in previous studies (23) . In contrast with general previous Polymorphism in hypertensive patients www.bjournal.com.br type plays an important role in resistant hypertension since this gene seems to amplify the effects of specific genotypes of other RAAS genes.
Association analysis between the anthropometric profile and hypertension risk indicated that age, BMI, and sex were the most important risk factors for resistant hypertension development in Brazilian patients. The present results support previous clinical and epidemiological studies which prove that a sedentary life style, physical inactivity, smoking, dyslipidemia, and alcohol and sodium intake are also external factors influencing the development of hypertension (31) (32) (33) .
Finally, the risk M235T-A1166C-C344T-A4582C haplotype and clinical risk factors (sex, BMI, age) collaborate in the development of resistant hypertension observed in Brazilian patients. These data emphasize the need to test an extensive set of genetic and clinical biomarkers in cases of multifactorial diseases in order to obtain accurate results. The use of hypertension biomarkers may provide useful information on pathogenetic mechanisms and on subsequent therapeutic approaches in selected individuals. Furthermore, the genetic evaluation of RAAS molecular variants associated with clinical analysis may contribute to the personalized diagnosis of severe forms of hypertension in the future.
